Emily Labriola–Tompkins

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati et al. · British Journal of Cancer · 2020 · 115 citations · Full text

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

Benoît Trottier, Sharon Walmsley, Jacques Reynes et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 81 citations

Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis.

G Ju, Emily Labriola–Tompkins, Carolyn A. Campen et al. · Proceedings of the National Academy of Sciences · 1991 · 72 citations · Full text

Site-specific Mutagenesis, Immunology, Receptor Antagonist +18

Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor.

Emily Labriola–Tompkins, Chitra Chandran, K L Kaffka et al. · Proceedings of the National Academy of Sciences · 1991 · 71 citations · Full text

Type Ii Il-1r, Immune Regulation, Immunology +17

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial

Sumathi Sivapalasingam, David J. Lederer, Rafia Bhore et al. · Clinical Infectious Diseases · 2022 · 39 citations · Full text